Edit

Qumra Capital

https://www.qumracapital.com
Last activity: 14.09.2026
Probably Closed
Portfolio
7
Mentions
45
Investment Type: Venture Capital
Investment Stage: Series C

Portfolio 7

DateNameWebsiteTotal RaisedLocation
12.08.2026Remepyremepy.com$51MIsrael
04.08.2026Quant Heal...quanthealth.ai$77MIsrael
03.08.2026Zenityzenity.io$184.5MUnited Sta...
16.07.2026TytoCaretytocare.com$303.5MUnited Sta...
30.03.2026Qodo AIqodo.ai$110MUnited Sta...
21.01.2026DataRailsdatarails.com$163.5MIsrael
09.10.2025Sensi.aisensi.ai$93.5MUnited Sta...

Mentions in press and media 45

DateTitleDescription
14.09.2026Buildots Raises $130M to Scale Construction IntelligenceBuildots Raises $130M As Construction AI Demand Grows Buildots has raised $130 million to expand its AI-powered construction intelligence platform. O.G. Venture Partners led the financing. Lightspeed Venture Partners and Intel Capital also ...
20.08.2026Remepy Raises $36 Million Series A, Bringing Total Funding To $62 Million As Parkinson’s Hybrid Drug Heads Toward Phase IIIRemepy has raised $36 million in Series A financing to advance its pipeline of Hybrid Drugs, including global Phase III development of Hybridopa for Parkinson’s disease, bringing the company’s total capital raised to $62 million. The round ...
16.08.2026Remepy Secures $36 Million Series A, Propelling Hybrid Drug InnovationRemepy, a New York biotech, secured $36 million in Series A funding. Total raised hits $62 million. O.G. Venture Partners and M Ventures led the round. Funds drive Hybrid Drug development and Parkinson's program, Hybridopa, into global Phas...
12.08.2026Remepy Snares $36 Million Series A NEW YORK, NY, Remepy, the pioneer of Hybrid Drugs, announced the closing of a $36 million Series A financing round led by O.G. Venture Partners and M Ventures. >> Click here for more funding data on Remepy >> To export Remepy f...
12.08.2026Remepy Raises $36M in Series A FundingRemepy, a NYC-based provider of a platform for hybrid drugs that combine prescription medicines with personalized, AI-driven therapeutic apps, raised $36M in Series A funding. The round was led by O.G. Venture Partners and M Ventures, with ...
07.08.2026AI Revolutionizes Drug Trials: QuantHealth Secures $45M to Predict SuccessQuantHealth raises $45M in Series B funding. Its AI platform simulates clinical trials. This drastically cuts drug development costs and failure rates. The technology boasts 90% predictive accuracy. It optimizes trial designs for major phar...
05.08.2026Zenity Raises $125 Million Series C NEW YORK, NY, Zenity, the AI security and governance platform purpose-built for AI agents, announced a $125 million Series C led by Norwest. >> Click here for more funding data on Zenity >> To export Zenity funding data to PDF ...
04.08.2026Beyond Real-World Trial Iteration: QuantHealth Secures $45M for AI Clinical SimulationWhat You Should Know Tel Aviv-based AI clinical simulation platform QuantHealth closed a $45 million Series B financing round led by Qumra Capital. The round saw participation from major strategic and venture investors, including Sanofi Ven...
04.08.2026Venture Capital & Startup Funding Roundup, August 4, 2026: a16z, Dream Ventures, JPMorgan, Sequoia Capital, SoftBank Vision Fund 2, YC & MoreInvestment today underscored that “big bets” in AI, energy infrastructure and next‑gen security are dominating capital flows. A $1 billion Series B for Valar Atomics and a $1 billion Series D for Base Power – both tied to powering AI worklo...
04.08.2026QuantHealth Raises $45M to Let Pharm Test Clinical Trials with AI Before Spending BillionsDrug development is a gamble. More than 90% of drugs that enter clinical trials fail. Three out of four of those failures are because the drug didn’t work or wasn’t safe. And by the time you find out, you’ve already spent years and hundreds...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In